BMO Upgrades Biogen (BIIB) to Market Perform Following Positive Trial Results for Oral BG-12
Go back to BMO Upgrades Biogen (BIIB) to Market Perform Following Positive Trial Results for Oral BG-12| BIOGEN IDEC Inc. (NASDAQ: BIIB) | Delayed: 209.03 -0.8 (0.38%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $209.83 | 52 Week High | $333.65 | |||
| Open | $208.36 | 52 Week Low | $223.02 | |||
| Day High | $210.32 | P/E | 26.76 | |||
| Day Low | $207.62 | EPS | $7.81 | |||
| Volume | 98,761 | |||||
